IDEAYA Biosciences, Inc. Common Stock vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| IDYA | LLY | |
|---|---|---|
| Market Cap | $3.66 billion | $1.09 trillion |
| Revenue (TTM) | $234.13 million | $79.67 billion |
| Net Income (TTM) | $-175,020,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| IDYA | LLY | |
|---|---|---|
| P/E Ratio | — | 42.98 |
| Price / Book | 3.05 | 32.25 |
| Price / Sales | 15.63 | 13.71 |
IDYA and LLY split the valuation factors evenly.
Profitability
| IDYA | LLY | |
|---|---|---|
| Net Margin | -74.75% | 33.53% |
| Return on Equity | -14.60% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Dividend
| IDYA | LLY | |
|---|---|---|
| Dividend Yield | — | 0.54% |
| Payout Ratio | — | 23.23 |
IDYA and LLY split the dividend factors evenly.
Risk & Sentiment
| IDYA | LLY | |
|---|---|---|
| Short Interest | 0.14% | 1.29% |
IDYA leads on 1 of 1 risk & sentiment factors.
Dig deeper: IDYA overview, IDYA financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.